TOBREX
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOBREX is a tobramycin ophthalmic solution approved in 1980 for bacterial eye infections. It is a small-molecule aminoglycoside antibiotic administered as eye drops. The drug works by inhibiting bacterial protein synthesis to treat ocular infections.
$0.057BPart D
LOE ApproachingLimited commercial opportunity as product approaches loss of exclusivity with minimal linked job openings and declining lifecycle stage.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle
Started Dec 2006
0Post-surgical Inflammation
Career Relevance
TOBREX offers very limited career opportunities due to zero linked job openings and LOE-approaching status. Roles available are typically focused on commercial wind-down, generic transition management, and compliance rather than growth or innovation.
Brand Manager
Worked on TOBREX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.